BioStem Technologies, Inc.: shareholders and insiders

BSEMNASDAQHealthcare · Biological Products, (No Diagnostic Substances)New listingsince Aug 6, 2026

Price

$0.96

November 16, 2026Market cap $18M

Insiders and their shares

Purchases and sales by officers and directors from Aug 9, 2026 to Nov 13, 2026, from their own Form 4 filings.

18 Form 4s

Bought on the market

–

nobody

Sold on the market

–

nobody

From Nov 17, 2025 to Nov 17, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

  • Nov 11, 2026Brandon PoeChief Financial Officer
    Kind
  • Nov 9, 2026Michael A FortunatoChief Accounting Officer
    Kind
  • Nov 1, 2026Barry HassettChief Commercial Officer
    Kind
  • Oct 7, 2026Vurst Andrew Smith-vanChief Operating Officer
    Kind
  • Oct 7, 2026Jason MatuszewskiChief Executive Officer
    Kind
  • Sep 17, 2026Vurst Andrew Smith-vanChief Operating Officer
    Kind
  • Sep 17, 2026Jason MatuszewskiChief Executive Officer
    Kind
  • Sep 15, 2026Brandon PoeChief Financial Officer
    Kind
  • Sep 15, 2026Vurst Andrew Smith-vanChief Operating Officer
    Kind
  • Sep 15, 2026Jason MatuszewskiChief Executive Officer
    Kind
  • Sep 15, 2026Kenneth Howard Warrington JrDirector
    Kind
  • Sep 15, 2026Michael A FortunatoChief Accounting Officer
    Kind
  • Sep 9, 2026Barry HassettChief Commercial Officer
    Kind
  • Aug 27, 2026Jodi UngrodtDirector
    Kind
  • Aug 27, 2026Hannaway Rayna LesserDirector
    Kind
  • Aug 27, 2026Mark A GlickmanDirector
    Kind
  • Aug 27, 2026Kenneth Howard Warrington JrDirector
    Kind
  • Aug 27, 2026Steven D SonenreichDirector
    Kind
  • Aug 11, 2026Brandon PoeChief Financial Officer
    Kind
  • Aug 9, 2026Michael A FortunatoChief Accounting Officer
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

3 Holders over 5%Nov 10, 2026 Latest filing
  • Andrew Van Vurst
    Share of class18.4%
  • Jason Matuszewski
    Share of class17.4%
  • The PNC Financial Services Group, Inc.
    Share of class10.4%

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

No well-known manager

None of the managers we track held BioStem Technologies shares in their latest 13F.

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 333.8K shares were held short, +239.1% since the report before.

Shares held short
333.8K
Since the report before98.5K on Sep 30, 2026
+239.1%
3.0
110.4K
More days to cover thanof 4,578 US-listed companies with enough volume
35%
Report date
Oct 15, 2026
  • Aug 14, 2026: Shares held short 554.2K
  • Aug 31, 2026: Shares held short 119.2K
  • Sep 15, 2026: Shares held short 133.9K
  • Sep 30, 2026: Shares held short 98.5K
  • Oct 15, 2026: Shares held short 333.8K

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading62.8% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 62.8% of the shares in the reported trades were short sales, against 73.4% in the 14 before.

Last 14 sessionsOct 28, 2026 – Nov 16, 2026
62.8%
The 14 beforeOct 8, 2026 – Oct 27, 2026
73.4%
Change
-10.6 pts
Short sales a dayon average, of 218.7K shares
137.3K
More than atof 3,668 US-listed companies, same days
88%
Median of alleight in ten from 34.7% to 63.8%
50.3%
  • Oct 8, 2026: Short sales 80.9%
  • Oct 9, 2026: Short sales 81.7%
  • Oct 12, 2026: Short sales 49.5%
  • Oct 13, 2026: Short sales 44.1%
  • Oct 14, 2026: Short sales 45.4%
  • Oct 15, 2026: Short sales 60.5%
  • Oct 16, 2026: Short sales 47.4%
  • Oct 19, 2026: Short sales 82.8%
  • Oct 20, 2026: Short sales 82.2%
  • Oct 21, 2026: Short sales 76.6%
  • Oct 22, 2026: Short sales 69%
  • Oct 23, 2026: Short sales 87.2%
  • Oct 26, 2026: Short sales 74.1%
  • Oct 27, 2026: Short sales 59.4%
  • Oct 28, 2026: Short sales 72.2%
  • Oct 29, 2026: Short sales 61.1%
  • Oct 30, 2026: Short sales 49.1%
  • Nov 2, 2026: Short sales 65.6%
  • Nov 3, 2026: Short sales 60.9%
  • Nov 4, 2026: Short sales 69.9%
  • Nov 5, 2026: Short sales 50.8%
  • Nov 6, 2026: Short sales 46.9%
  • Nov 9, 2026: Short sales 44.3%
  • Nov 10, 2026: Short sales 60.8%
  • Nov 11, 2026: Short sales 68.4%
  • Nov 12, 2026: Short sales 55.7%
  • Nov 13, 2026: Short sales 73.5%
  • Nov 16, 2026: Short sales 47.7%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

3.55M Insiders' shares
  • Vurst Andrew Smith-vanChief Operating Officer
    Directly1.79M
  • Jason MatuszewskiChief Executive Officer
    Directly1.55M
  • Michael A FortunatoChief Accounting Officer
    Directly69.6K
  • Brandon PoeChief Financial Officer
    Directly60.8K
  • Kenneth Howard Warrington JrDirector
    Directly33.9K
  • Jodi UngrodtDirector
    Directly11.3K
  • Hannaway Rayna LesserDirector
    Directly7,671
  • Mark A GlickmanDirector
    Directly7,671
  • Steven D SonenreichDirector
    Directly7,671
  • Barry HassettChief Commercial Officer
    Directly5,256

A lower bound: it counts only the 10 officers and directors with a market trade since Nov 18, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

Questions about BSEM's shareholders

Didn't find what you were looking for?

Ask us
Have BSEM's insiders bought or sold?

From Aug 20, 2026 to Nov 13, 2026 BioStem Technologies's insiders reported no purchase or sale of shares on the market.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.